2-5A ligands--a new concept for the treatment of prostate cancer

Nucleosides Nucleotides Nucleic Acids. 2007;26(10-12):1471-7. doi: 10.1080/15257770701542652.

Abstract

Several potent prostate specific membrane antigen (PSMA) inhibitors have been described recently. We generated a PSMA-specific 2-5A ligand called RBI 1033 by linking 2-5A to the N-acetylaspartylglutamate (NAAG)-based inhibitor ZJ-24. We measured the inhibitory activity of RBI 1033 to the folate hydrolase activity of PSMA. Amazingly, we found that compared to ZJ-24 (IC50 = 53.9 nM), RBI 1033 was more than 10 times more potent (IC50 = 4.78 nM) as a folate hydrolase inhibitor, while SMCC 2-5A lacking the ZJ-24 part, did not show much activity (IC50 = 1974 nM). Also, RBI 1033's affinity to PSMA was found to be 10 times higher than ZJ-24 itself.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenine Nucleotides / chemistry
  • Adenine Nucleotides / pharmacology*
  • Adenine Nucleotides / therapeutic use
  • Antigens, Surface / chemistry
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Endoribonucleases / chemistry
  • Glutamate Carboxypeptidase II / antagonists & inhibitors*
  • Glutamate Carboxypeptidase II / chemistry
  • Humans
  • Ligands
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / enzymology

Substances

  • Adenine Nucleotides
  • Antigens, Surface
  • Antineoplastic Agents
  • Ligands
  • RBI 1033
  • Endoribonucleases
  • 2-5A-dependent ribonuclease
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II